文献速递胸部肿瘤

STK11/LKB1突变与KRAS突变肺腺癌PD-1抑制剂耐药

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
PubMed 文献 · Cancer Discov · 2018-05-17

该研究在KRAS突变肺腺癌中分析STK11/LKB1(KL)、TP53(KP)共突变亚组对PD-1抑制剂疗效的差异。SU2C队列(174例)中客观缓解率KL 7.4%、KP 35.7%、K-only 28.6%(P<0.001),CheckMate-057中分别为0%、57.1%、18.2%(P=0.047)。KL亚组无进展生存和总生存更短,STK11/LKB1改变是PD-1阻断原发耐药的主要驱动因素。

要点

  • KRAS突变肺腺癌中STK11/LKB1共突变者PD-1抑制剂客观缓解率仅7.4%。
  • KL亚组无进展生存和总生存显著短于STK11/LKB1野生型。
  • STK11/LKB1改变是TMB中/高肺腺癌中唯一与PD-L1阴性相关的标志物。

核心结论

  • STK11/LKB1改变是KRAS突变肺腺癌对PD-1阻断原发耐药的主要驱动因素。

研究设计与样本

  • 研究分析SU2C队列174例KRAS突变肺腺癌患者及CheckMate-057 III期试验中纳武利尤单抗治疗患者。
  • 另在924例肺腺癌中分析STK11/LKB1改变与PD-L1表达及TMB的关联。
  • 使用Kras突变小鼠肺腺癌模型验证Stk11/Lkb1缺失对PD-1/PD-L1抑制剂耐药的影响。

主要发现

  • SU2C队列中PD-1阻断客观缓解率KL 7.4%、KP 35.7%、K-only 28.6%(P<0.001)。
  • CheckMate-057中客观缓解率KL 0%、KP 57.1%、K-only 18.2%(P=0.047)。
  • SU2C队列中KL肺腺癌无进展生存(P<0.001)和总生存(P=0.0015)短于KRASMUT;STK11/LKB1WT。
  • 924例肺腺癌中STK11/LKB1改变是TMB中/高肺腺癌中唯一与PD-L1阴性显著相关的标志物。
  • Kras突变小鼠模型中Stk11/Lkb1缺失促进PD-1/PD-L1抑制剂耐药。

关键数值与推荐

  • SU2C队列174例KRAS突变肺腺癌,PD-1阻断客观缓解率KL 7.4%、KP 35.7%、K-only 28.6%(P<0.001)。
  • CheckMate-057中纳武利尤单抗治疗患者客观缓解率KL 0%、KP 57.1%、K-only 18.2%(P=0.047)。
  • SU2C队列KL肺腺癌无进展生存P<0.001、总生存P=0.0015(对比KRASMUT;STK11/LKB1WT)。

临床怎么用

  • 对KRAS突变肺腺癌进行STK11/LKB1基因组分析,辅助预判PD-1抑制剂原发耐药。
  • STK11/LKB1改变可扩展至PD-L1阳性非小细胞肺癌的PD-1/PD-L1抑制剂疗效预测。
  • 基因组分型可能帮助为特定肺腺癌亚组制定个体化联合免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1-positive non-small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC.Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822-35. ©2018 AACR.See related commentary by Etxeberria et al., p. 794This article is highlighted in the In This Issue feature, p. 781.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018. PMID: 29773717. doi:10.1158/2159-8290.CD-18-0099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。